The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
Open accessAbstract
The echinocandins are being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for the emergence of in vitro resistance to the echinocandins among invasive Candida sp. isolates is indicated. We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 5,346 invasive (bloodstream or sterile-site) isolates of Candida spp. collected from over 90 medical centers worldwide from 1 January 2001 to 31 December 2006. We performed susceptibility testing according to the CLSI M27-A2 method and used RPMI 1640 broth, 24-h incubation, and a prominent inhibition endpoint for determination of the MICs. Of 5,346 invasive Candida sp. isolates, species distribution was 54% C. albicans , 14% C. parapsilosis , 14% C. glabrata , 12% C. tropicalis , 3% C. krusei , 1% C. guilliermondii , and 2% other Candida spp. Overall, all three echinocandins were very active against Candida : anidulafungin (MIC 50 , 0.06 μg/ml; MIC 90 , 2 μg/ml), caspofungin (MIC 50 , 0.03 μg/ml; MIC 90 , 0.25 μg/ml), micafungin (MIC 50 , 0.015 μg/ml; MIC 90 , 1 μg/ml). More than 99% of isolates were inhibited by ≤2 μg/ml of all three agents. Results by species (expressed as the percentages of isolates inhibited by ≤2 μg/ml of anidulafungin, caspofungin, and micafungin, respectively) were as follows: for C. albicans , 99.6%, 100%, and 100%; for C. parapsilosis , 92.5%, 99.9%, and 100%; for C. glabrata , 99.9%, 99.9%, and 100%; for C. tropicalis , 100%, 99.8%, and 100%; for C. krusei , 100%, 100%, and 100%; and for C. guilliermondii , 90.2%, 95.1%, and 100%. There was no significant change in the activities of the three echinocandins over the 6-year study period and no difference in activity by geographic region. All three echinocandins have excellent in vitro activities against invasive strains of Candida isolated from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging echinocandin resistance among invasive clinical isolates of Candida spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“wild-type strains from those with target site mutations (31, 38).”
BackgroundSelf-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · cited 3×
“tion (FDA; years 2002 and 2006, respectively) for the treatment of invasive candidiasis, including candidemia (20, 40),”
BackgroundKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Pfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423
Self-citationDouglas, C. M., D'Ippolito, J. A., Shei, G. J., Meinz, M., Onishi, J., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A., Bartizal, K., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344
Candida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Manual of Clinical Microbiology · doi:10.1128/9781555816728.ch115 · Cited by 246
Moudgal, V., Little, T., Boikov, D., & Vazquez, J. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.767-769.2005 · Cited by 242
(2003) · PubMed · Cited by 240
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
de Wet, N., Cuentas, A. L., Suleiman, J., Baraldi, E., Krantz, E. F., Della Negra, M., & Diekmann-Berndt, H. (2004) · Clinical Infectious Diseases · doi:10.1086/423377 · Cited by 204
Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201
Pfaller, M. A., Diekema, D. J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.-C., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 194
Self-citationIn Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 193
Self-citationLaverdière, M., Lalonde, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Odds, F. C., Motyl, M., Andrade, R., Bille, J., Cantón, E., Cuenca-Estrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3475-3482.2004 · Cited by 173
Self-citationHernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.11.5425-5427.2005 · Cited by 161
Self-citationEmergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy
Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138
The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications
Wagner, C. C., Graninger, W., Presterl, E., & Joukhadar, C. (2006) · Pharmacology · doi:10.1159/000096348 · Cited by 137
Kurtz, M., Abruzzo, G. K., Flattery, A. M., Bartizal, K. F., Marrinan, J. A., Li, W., Milligan, J. A., Nollstadt, K. H., & Douglas, C. M. (1996) · Infection and Immunity · doi:10.1128/iai.64.8.3244-3251.1996 · Cited by 136
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118
Echinocandins for Candidemia in Adults without Neutropenia
Bennett, J. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmct060052 · Cited by 111
Serum Differentially Alters the Antifungal Properties of Echinocandin Drugs
Paderu, P., García‐Effrón, G., Balashov, S. V., Delmas, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01536-06 · Cited by 111
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98
Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp
Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., & Pfaller, M. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.324-326.2006 · Cited by 97
Self-citationProgressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93
Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3117-3119.2004 · Cited by 90
Self-citationPfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00872-06 · Cited by 88
Self-citationPelletier, R., Alarie, I., Lagacé, R., & Walsh, T. J. (2005) · Medical Mycology · doi:10.1080/13693780500220415 · Cited by 67
Nelson, P. W., Lozano‐Chiu, M., & Rex, J. H. (1997) · Medical Mycology · doi:10.1080/02681219780001291 · Cited by 51
Prabhu, R. M., & Orenstein, R. (2004) · Clinical Infectious Diseases · doi:10.1086/424449 · Cited by 47
Efficacy of micafungin for the treatment of candidemia
Andes, D. R., & Safdar, N. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0025-7 · Cited by 14
Voriconazole and Caspofungin Cidality Against Non-Albicans Candida Species
Isham, N. C., & Ghannoum, M. A. (2007) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318059b94b · Cited by 13
ECHINOCANDIN ANTIFUNGAL DRUG RESISTANCE
Rogers, T., Johnson, E., & Munro, C. A. (2007) · Cited by 8
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationCandida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Self-citation
Metadata
- Authors
- Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2008-01
- Volume
- 46
- Issue
- 1
- Pages
- 150-156
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W1994613828
- Cited by
- 387
- References
- 43
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.